Scott Powers initiated coverage on Rhinomed in Mar 2014 with a price target of 0.08. This was revised lower to 0.06 in Feb 2015 and increased to 0.07. Note he calls this a speculative investment.
Am trying not to get caught too caught up in the upside/downside hype of this one. Good luck to all holders.